12 months ago, at ESMO 2021, the oncology community was asked, “Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?”.
At that time, 71% felt the available efficacy data was not sufficient to implement neoadjuvant chemo-IO as a standard of care for resectable NSCLC.
However, a lot has changed since then.
In the past 12 months, the evidence and rationale for chemo-IO in the neoadjuvant setting for resectable NSCLC has been growing. Checkmate 816 reported improved EFS, nivolumab secured FDA approval, NCCN guidelines were updated, and survival data from phase II trials is favourable.
To understand current adoption and opinion of neoadjuvant chemo-IO for resectable NSCLC, we conducted n=6 in-depth interviews with global KOLs and a short poll among US oncologists and thoracic surgeons.
What did we learn? KOLs do consider chemo-IO as the preferred option for resectable NSCLC; but, outside key academic institutions, there is still further work to be done.
Read our article to find out more ….
Contact our Oncology Directors – Siobhan Davies at firstname.lastname@example.org or Lindsay Widger at email@example.com – for more information.